Insights
Essays on diagnosing and treating the hidden technology diseases that limit business growth — written for CEOs, boards and investors, not for engineering audiences.
Most CEO conversations begin with what's visible — growth, cost, releases, complaints. The real disease sits underneath the waterline in architecture, data, operating cadence and unspoken misalignment.
Read this if: you keep funding fixes and the same problems keep coming back.
Pattern selection should follow workload classification. Choosing architecture by reputation is one of the most expensive forms of misdiagnosis a CEO can fund.
Read this if: someone's pushing microservices, agents or event mesh and you're not sure why.
A diagnostic that doesn't change the CEO conversation is a diagnostic that wasn't done. These are the eight questions every Growth Blocker MRI Dx™ answers.
Read this if: you're about to commission a tech review and want it to change decisions.
If data, workflows, ownership and architecture are unhealthy, AI will only automate confusion — at a much faster rate.
Read this if: you're betting on AI to fix problems your org already can't.
Trimming reserved instances does not fix cost-leaking architecture. The treatment sits one layer below the FinOps dashboard.
Read this if: your cloud bill is climbing faster than your usage.
Engineering sees architecture friction. Product sees roadmap pressure. Finance sees rising cost. The diagnosis is the act of connecting them.
Read this if: every leader tells you a different story about the same problem.
A prescription that doesn't say what to stop is incomplete. The first 30 days are not for new initiatives — they are for stopping the wrong ones.
Read this if: you want to know what real progress looks like in the first 30 days.
Most diligence reads as a vendor list. Useful diligence reads as a disease list — with severity and treatment cost attached.
Read this if: you're about to invest and the tech diligence reads like a vendor list.
Most leadership teams misdiagnose delivery friction as a team issue. It is usually a platform, architecture or operating-cadence disease.
Read this if: your releases keep slipping and you're blaming the team.
Agentic AI is moving from demos to production. The companies that will compound are the ones that build governance before they build agents.
Read this if: your AI demos look great but nothing's safely in production.
The 'we need a new leader' reflex often hides the absence of a decision-rights, cadence and ownership system. New people inherit old diseases.
Read this if: your instinct is to hire a new VP to fix the problem.
No newsletter padding. Follow on LinkedIn for new essays and research as they go out — or message on WhatsApp to get the CEO memo direct: one named disease, one CEO-level question, one practical move.
Diagnosing and Treating Technology Diseases That Limit Business Growth.